口腔医学研究 ›› 2023, Vol. 39 ›› Issue (4): 362-369.DOI: 10.13701/j.cnki.kqyxyj.2023.04.016

• 颞下颌关节病学研究 • 上一篇    下一篇

液态浓缩生长因子联合透明质酸注射治疗对颞下颌关节骨关节炎的影响

赵琛1,2,3*, 姜杉杉1, 刘阳1,2,3, 吴素然1,2,3, 邱桐4, 白月辉1, 吴洁1,2,3, 贾语婧4   

  1. 1.河北医科大学口腔医学院·口腔医院修复科 河北 石家庄 050017;
    2.河北省口腔医学重点实验室 河北 石家庄 050017;
    3.河北省口腔疾病临床医学研究中心 河北 石家庄 050017;
    4.河北医科大学口腔医学院 河北 石家庄 050017
  • 收稿日期:2022-11-28 出版日期:2023-04-28 发布日期:2023-04-19
  • 通讯作者: *赵琛,E-mail:zhaochen36@163.com
  • 作者简介:赵琛(1977~ ),女,四川宣汉人,博士,副主任医师,研究方向:咬合病与颞下颌关节紊乱病。
  • 基金资助:
    河北省医学科学研究课题计划指导性课题(编号:20201193)2019年河北省财政厅老年病防治科研项目(编号:361029)河北省科技厅重点研发计划(编号:17277761D)河北医科大学创新性实验计划项目(编号:USIP2021199)

Effect of Liquid Phase Concentrated Growth Factor Combined with Hyaluronic Acid Injection on Temporomandibular Joint Osteoarthritis

ZHAO Chen1,2,3*, JIANG Shanshan1, LIU Yang1,2,3, WU Suran1,2,3, QIU Tong4, BAI Yuehui1, WU Jie1,2,3, JIA Yujing4   

  1. 1. Department of Prosthodontics, School and Hospital of Stomatology, Hebei Medical University, Shijiazhuang 050017, China;
    2. Hebei Key Laboratory of Stomatology, Shijiazhuang 050017, China;
    3. Hebei Clinical Research Center for Oral Disease, Shijiazhuang 050017, China;
    4. School and Hospital of Stomatology, Shijiazhuang 050017, China
  • Received:2022-11-28 Online:2023-04-28 Published:2023-04-19

摘要: 目的: 探讨自体液态浓缩生长因子(LPCGF)联合透明质酸(HA)注射治疗大鼠颞下颌关节骨关节炎(TMJOA)的效果。方法: 采用33只SD大鼠,空白对照组3只,实验组30只,通过颞下颌关节腔内注射Ⅱ型胶原酶的方法建立TMJOA模型,建模4周后,实验组随机选取3只作为未治疗组,其余大鼠为治疗组,并随机分为3组:HA治疗组(A组)、LPCGF治疗组(B组)、LPCGF和HA联合治疗组(C组)。治疗组每周进行1次关节腔注射治疗,治疗后的2、4、6周随机选取3只大鼠进行取材。对其髁突软骨苏木精-伊红(HE)和番红O-固绿染色后进行病理观察及评分,免疫组织化学染色检测白细胞介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)的表达水平。结果: 本实验成功建立大鼠TMJOA模型,HE和番红O-固绿染色结果显示,经注射治疗后可见髁突软骨及软骨下骨的修复,各治疗组改良Mankin’s的评分均有所降低。免疫组织化学结果显示,药物注射治疗可明显抑制关节软骨内炎症因子IL-1β、TNF-α的表达,且联合治疗组对炎症因子的抑制效果更强(P<0.05)。结论: 自体LPCGF和HA均能治疗大鼠TMJOA,但LPCGF联合HA注射治疗对髁突软骨的修复及抑制关节软骨内炎性细胞因子IL-1和TNF-α的作用更显著。

关键词: 颞下颌关节骨关节炎, 透明质酸, 浓缩生长因子, 白细胞介素-1β, 肿瘤坏死因子-α

Abstract: Objective: To investigate the effect of autologous liquid phase concentrated growth factor (LPCGF) combined with hyaluronic acid (HA) injection in the treatment of rat temporomandibular joint osteoarthritis (TMJOA). Methods: A total of 33 SD rats were used in the present study, including blank control group (n=3) and experimental group (n=30). Type Ⅱ collagenase was injected into bilateral TMJ cavity to establish TMJOA model. Three rats were randomly selected as the untreated group from experimental group, while the rest of experimental group was selected as treated group and was randomly divided into three subgroups, including HA group (A), LPCGF group (B), and combined treatment group (C). Each group was treated with intra-articular injection once a week, and the tissue samples of TMJ were acquired from three rats randomly every week for 2, 4, and 6 weeks after treatment. HE staining and Safranin O-fast green staining were performed to observe histological changes of the joints and evaluate according to the modified Mankin's score. Immunohistochemistry was performed to detect the changes of interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) in condylar cartilage. Results: Intra-articular injection of type II collagenase could successfully induce the rat TMJOA model. Histological observation revealed the repair of condylar cartilage and subchondral bone after injection treatment. The modified Mankin’s score was reduced in all treated groups (P>0.05). The immunohistochemical results showed that the expression of IL-1β and TNF-α in TMJ cartilage could be significantly inhibited by HA or LPCGF injection treatment, and the combined treatment group had the most significant inhibition effect (P<0.05). Conclusion: Both LPCGF and HA can treat temporomandibular joint osteoarthritis in rats. However, LPCGF combined with HA injection has the most significant effect on the modification of condylar and inhibition of IL-1 and TNF-α in articular cartilage (P<0.05).

Key words: temporomandibular joint osteoarthritis, hyaluronic acid, concentrated growth factor, interleukin-1β, tumor necrosis factor-α